After receiving approval from the European Medicines Agency (EMA) to commence its Phase I clinical study for LPH-5, Lophora has successfully completed an over $3 million capital raise to support this next phase and further bolster the company’s robust patent portfolio.
The financing round, which garnered strong interest from both new and existing investors, underscores confidence in Lophora’s innovative approach to CNS therapies. Industry veterans Tim Haines and Don deBethizy, known for their successful track records in biotech investment, continue to back the company, reinforcing Lophora’s potential to advance transformative treatments.
“This successful raise is a pivotal step forward for Lophora as we move LPH-5 into human clinical trials,” said Bo Tandrup, CEO of Lophora. “We are committed to developing next-generation therapies that address unmet needs in CNS disorders. With the support of our investors, we’re poised to make meaningful progress toward improving patient outcomes.”
LPH-5 is a proprietary psychedelic-based molecule designed to address CNS conditions where current treatment options are limited or ineffective. The upcoming Phase I study will focus on evaluating the safety, tolerability, and pharmacokinetic profile of LPH-5, marking a significant milestone in Lophora’s development pipeline.
Lophora’s innovative work in CNS drug discovery aims to harness the potential of new molecular entities to offer safer and more effective treatment options. With this financing secured, the company is set to initiate the Phase I trial in early 2025, with results anticipated later in the year.
For more information on Lophora and its groundbreaking research, please visit www.lophora.com.
About Lophora
Lophora is a biotech company at the forefront of CNS drug discovery, focusing on next-generation proprietary psychedelic compounds. With a mission to revolutionize treatment options for patients suffering from CNS disorders, Lophora leverages cutting-edge science and robust clinical development to bring innovative therapies to market.
Lophora is a biotech company at the forefront of CNS drug discovery, focusing on next-generation proprietary psychedelic compounds. With a mission to revolutionize treatment options for patients suffering from CNS disorders, Lophora leverages cutting-edge science and robust clinical development to bring innovative therapies to market.